Catalog #CP001

RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A)

Clone 10F.9G2™-CP001
Reactivities Mouse
Product Citations 1
Isotype Mouse IgG1 (D265A), k
(switched from rat IgG2b)

$560.00 - $7,581.50

$560.00 - $7.00

Choose an Option...
  • 25 mg - $7,581.50
  • 5 mg - $2,170.50
  • 1 mg - $560.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Description

The 10F.9G2™-CP001 monoclonal antibody is a recombinant chimeric version of the original 10F.9G2™ antibody. The variable domain sequences are identical to the original 10F.9G2™ but the constant region sequences have been switched from rat IgG2b to mouse IgG1. The 10F.9G2™-CP001 antibody also contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. The 10F.9G2™-CP001 antibody reacts with mouse PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L1 is expressed on T lymphocytes, B lymphocytes, NK cells, dendritic cells, as well as IFNγ stimulated monocytes, epithelial cells and endothelial cells. PD-L1 binds to its receptor, PD-1, found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Engagement of PD-L1 with PD-1 leads to inhibition of TCR-mediated T cell proliferation and cytokine production. PD-L1 is thought to play an important role in tumor immune evasion. Induced PD-L1 expression is common in many tumors and results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and PD-1. The 10F.9G2™ antibody has been shown to block the interaction between PD-L1 and PD-1 and between PD-L1 and B7-1 (CD80).

Specifications

Isotype Mouse IgG1, κ
Recommended Isotype Control(s) RecombiMAb mouse IgG1 (D265A) isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Mutations D265A
Immunogen Mouse CD274
Reported Applications in vivo PD-L1 blockade*
Immunofluorescence*
Immunohistochemistry (frozen)*
Flow cytometry*
Western blot*
*Reported for the original rat IgG2b 10F.9G2 antibody
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin ≤0.5EU/mg (≤0.0005EU/μg)
Determined by LAL assay
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from HEK293 cell supernatant in an animal-free facility
Purification Protein A
Molecular Weight 150 kDa
Murine Pathogen Tests Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
K Virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Lymphocytic Choriomeningitis virus: Negative
Mouse Adenovirus: Negative
Mouse Cytomegalovirus: Negative
Mouse Hepatitis Virus: Negative
Mouse Minute Virus: Negative
Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Rotavirus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Polyoma Virus: Negative
Reovirus Screen: Negative
Sendai Virus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options

Product Citations

    • Cancer Research
    • Immunology and Microbiology
    IL33-induced lipid droplet formation in mature low-density neutrophils drives colorectal cancer liver metastasis.

    In Cell Mol Immunol on 1 December 2025 by Zhang, Y., Yu, S., et al.

    PubMed

    The microenvironment of distant organs affects the colonization and growth of disseminated tumor cells. It remains unclear how tumor-associated neutrophils are influenced by the microenvironment of distant organs. Here, we demonstrate that mature low-density neutrophils in colorectal cancer patients abnormally accumulate neutral lipids and induce the reactivation of dormant tumor cells, a process regulated by hepatic stellate cells. Mechanistically, activated hepatic stellate cells increased DGAT1/2-dependent lipid droplet synthesis in low-density neutrophils through the secretion of IL33, thereby maintaining the survival and immunosuppressive function of these neutrophils. The uptake of lipids from lipid-laden low-density neutrophils drives dormant tumor cell reactivation through the potentiation of β-oxidation and the stimulation of protumorigenic eicosanoid synthesis. In mouse models, targeting IL33 blocked neutrophil lipid synthesis, decreased the colonization of colorectal cancer cells in the liver, and enhanced the efficacy of immunotherapy. Overall, our study revealed that lipid accumulation in mature low-density neutrophils regulates the growth of dormant tumor cells and antitumor immunity to facilitate colorectal cancer liver metastasis. Targeting IL33 could be a promising therapeutic approach for colorectal cancer liver metastases.

View More

Product FAQs

Related Products

  1. Catalog #CP168
    RecombiMAb anti-mouse PD-L1 (B7-H1) Read more
  2. Catalog #BE0361
    InVivoMAb anti-mouse PD-L1 (B7-H1) Read more
  3. Catalog #SIM0009
    InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) Read more
  4. Catalog #BE0285
    InVivoMAb anti-human PD-L1 (B7-H1) Read more
  5. Catalog #BP0101
    InVivoPlus anti-mouse PD-L1 (B7-H1) Read more
  6. Catalog #BE0101
    InVivoMAb anti-mouse PD-L1 (B7-H1) Read more
  7. Catalog #BE0383
    InVivoMAb anti-mouse/human/rat PD-L1 Read more
  8. Catalog #SIM0021
    InVivoSIM anti-human PD-L1 (Avelumab Biosimilar) Read more
  9. Catalog #BE0390
    InVivoMAb anti-canine PD-L1 (B7-H1) Read more
  10. Catalog #SIM0027
    InVivoSIM anti-human PD-L1 (Durvalumab Biosimilar) Read more
  11. Catalog #CP154
    RecombiMAb anti-mouse PD-L1 (B7-H1) (LALA-PG) Read more
  12. Catalog #CP158
    RecombiMAb anti-mouse PD-L1 (B7-H1) Read more

Additional Formats

  1. Catalog #BE0101
    InVivoMAb anti-mouse PD-L1 (B7-H1) Read more
  2. Catalog #BP0101
    InVivoPlus anti-mouse PD-L1 (B7-H1) Read more
  3. Catalog #CP154
    RecombiMAb anti-mouse PD-L1 (B7-H1) (LALA-PG) Read more
  4. Catalog #CP158
    RecombiMAb anti-mouse PD-L1 (B7-H1) Read more
  5. Catalog #CP168
    RecombiMAb anti-mouse PD-L1 (B7-H1) Read more